Panitumumab (powder)
Based on 3 publication(s) in Google Scholar
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 339177-26-3
- Molecular Weight:144.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Panitumumab (powder)
More
Customer Validation & Images
-
WB
-
IF
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Panitumumab (2 nM-2 μM, 3 h) (powder) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) (powder)inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) (powder) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
-
Concentration:2, 20, 200, 2000 nM
-
Incubation Time:3 h
-
Result:Inhibited ligand-induced autophosphorylation of EGFR.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H1975 and NCI-H1650 xenografts[3]
-
Dosage:25, 100, or 500 μg/mouse
-
Administration:Intraperitoneal injection (i.p.), twice a week
-
Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
- Human pluripotent stem cell endothelial-cell differentiation
- Vascular/Branching Fractal Analysis
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Endothelial Tube Formation Assay
- MTT Cell Proliferation Assay
- Endothelial Cell Migration/Angiogenic Sprouting Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 339177-26-3
-
Molecular Weight 144.32 kDa
-
SMILES
[Panitumumab (powder)]
-
Synonyms
ABX-EGF (powder)
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
Sci Rep
Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. [Abstract]2022 Jul 7;12(1):11561. PMID: 35798841
Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]
HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.
Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]
Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.
-
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887
Purity & Documentation
References
[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]
[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]
[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]
[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Panitumumab (powder) Related Classifications
HY-P99041B Related Classifications
Powered by Bioz